Volume 3 | Issue 1 | DOI: https://doi.org/10.33696/haematology.3.041
Commentary on "The FLAMSA Concept Past and Future"
- 1Clinical Cooperative Group Haematopoietic Cell Transplantation; Dept. Medicine III, Klinikum Grosshadern, University of Munich, Germany, And Helmholtz Zentrum Muenchen, Muenchen, Germany
- 2 Ribeirao Preto Medical School, University of Sao Paulo, Brazil
- 3Universitaetsklinikum Augsburg, Dept Med II, Augsburg, Germany
Hans-Jochem Kolb, email@example.com
Received Date: December 03, 2021
Accepted Date: January 24, 2022
Kolb HJ, Simoes BP, Schmid C. Commentary on ”The FLAMSA Concept Past and Future”. J Clin Haematol. 2022;3(1):1-8.
Copyright: © 2022 Kolb HJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Karyotypic Profile of Chronic Myeloid Leukemia in Patients Diagnosed at Tertiary Level in Afghanistan
Balanced translocation resulting in fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2 is the pathognomonic molecular driver of CML. The resulting BCRABL 1 fusion gene is both the diagnostic as well as therapeutic target of CML. The first agent with tyrosine kinase inhibitor activity that was licenced in 2000 for treatment of CML patients, was Imatinib, gradually followed by multiple agents with higher efficacy.
Breast cancer is the second most common cancer worldwide, affecting nearly one in eight women. Accurate cancer staging is essential for determining the patient’s prognosis and for choosing the appropriate treatment.
Molecular Biology for BCR-ABL1 Quantification for Chronic Myeloid Leukemia Monitorization and Evaluation
Chronic Myeloid Leukemia (CML) is a clonal disorder originated by a pluripotent hematopoietic stem cell, which presents the translocation t(9;22) (q34;q11) in 90% of the cases.
In 2020 we published a series of 18 patients who underwent neoadjuvant chemotherapy (NACT) and vaginal radical trachelectomy (VRT) as a fertility sparing alternative in stage 1B2 cervical cancer.
Introducing cisplatin-based therapy into testicular cancer treatment represents a substantial progress in therapy leading to a longer survival of patients and less adverse effects; currently it represents the standard therapy.